TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $124.20.

Several brokerages recently issued reports on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 price objective (up from $90.00) on shares of TransMedics Group in a research note on Tuesday. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, April 23rd.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently made changes to their positions in TMDX. Virtu Financial LLC acquired a new stake in TransMedics Group in the third quarter valued at approximately $436,000. Morse Asset Management Inc bought a new position in shares of TransMedics Group in the third quarter valued at $823,000. Wilmington Savings Fund Society FSB acquired a new position in TransMedics Group during the 3rd quarter valued at about $149,000. Principal Financial Group Inc. raised its stake in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Finally, APEIRON CAPITAL Ltd bought a new position in shares of TransMedics Group in the fourth quarter valued at approximately $468,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.5 %

Shares of NASDAQ TMDX opened at $89.98 on Monday. The firm has a 50 day moving average price of $76.02 and a two-hundred day moving average price of $76.72. The stock has a market cap of $3.04 billion, a P/E ratio of 95.72 and a beta of 2.14. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.